The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
MedPage Today on MSN3d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
News-Medical.Net on MSN13h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback